GlaxoSmithKline and Praecis Pharmaceuticals, Inc. entered into a definitive agreement whereby GSK will acquire all outstanding shares of Praecis for a total of approximately $54.8 million. Praecis, a biopharmaceutical company, has a novel MetAP-2 inhibitor, PPI-2458, in clinical development for cancer indications, including non-Hodgkin’s lymphoma and solid tumors, a drug discovery technology, DirectSelect, which enables the generation of large libraries for the discovery of orally act...